- Home
- D vs INSM Comparison
D vs INSM Comparison
Compare D & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | D | INSM |
|---|---|---|
| Founded | 1983 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.7B | 41.2B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | D | INSM |
|---|---|---|
| Price | $59.51 | $176.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | $64.75 | ★ $185.84 |
| AVG Volume (30 Days) | ★ 6.9M | 4.5M |
| Earning Date | 10-31-2025 | 10-30-2025 |
| Dividend Yield | ★ 4.49% | N/A |
| EPS Growth | ★ 21.14 | N/A |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $15,813,000,000.00 | $447,022,000.00 |
| Revenue This Year | $11.56 | $43.10 |
| Revenue Next Year | $6.47 | $128.25 |
| P/E Ratio | $19.37 | ★ N/A |
| Revenue Growth | 8.36 | ★ 30.34 |
| 52 Week Low | $48.07 | $60.40 |
| 52 Week High | $62.87 | $212.75 |
Technical Indicators
Market Signals| Indicator | D | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 38.73 |
| Support Level | $58.95 | $161.02 |
| Resistance Level | $59.16 | $205.23 |
| Average True Range (ATR) | 0.94 | 7.46 |
| MACD | 0.05 | -4.01 |
| Stochastic Oscillator | 56.32 | 29.56 |
Price Performance
Historical ComparisonAbout D Dominion Energy Inc.
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion is constructing a rate-regulated 5.2 GW wind farm off the Virginia Beach coast.
About INSM Insmed Incorporated
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.